{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:10:58Z","timestamp":1783987858483,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"grant VEGA","award":["1\/0048\/23"],"award-info":[{"award-number":["1\/0048\/23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52621-5","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:46:52Z","timestamp":1778662012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protection against isoproterenol-induced cardiac injury by sacubitril\/valsartan is associated with upregulation of the alternative renin-angiotensin-aldosterone system pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Fedor","family":"Simko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Baka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Repova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Krajcirovicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Aziriova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Adamcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"52621_CR1","doi-asserted-by":"publisher","first-page":"C3","DOI":"10.1016\/0002-9149(93)90081-M","volume":"71","author":"M Packer","year":"1993","unstructured":"Packer, M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am. J. Cardiol. 71, C3\u2013C11 (1993).","journal-title":"Am. J. Cardiol."},{"key":"52621_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/01.hjh.0000388487.43460.db","volume":"28","author":"F Simko","year":"2010","unstructured":"Simko, F. & Pechanova, O. Remodelling of the heart and vessels in experimental hypertension: Advances in protection. J. Hypertens. 28, S1\u2013S6 (2010).","journal-title":"J. Hypertens."},{"issue":"1","key":"52621_CR3","first-page":"1","volume":"48","author":"F Simko","year":"1998","unstructured":"Simko, F. & Simko, J. Heart failure and angiotensin converting enzyme inhibition: Problems and perspectives. Physiol. Res. 48(1), 1\u20138 (1998).","journal-title":"Physiol. Res."},{"key":"52621_CR4","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026215712983","author":"F Simko","year":"2003","unstructured":"Simko, F., Simko, J. & Fabryova, M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: Pathophysiological consideration of the unresolved battle. Cardiovasc. Drugs Ther. https:\/\/doi.org\/10.1023\/a:1026215712983 (2003).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"52621_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray, J. J. V. et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371, 993\u20131004 (2014).","journal-title":"N Engl J Med"},{"key":"52621_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.250","volume":"17","author":"JJV McMurray","year":"2015","unstructured":"McMurray, J. J. V. Neprilysin inhibition to treat heart failure: A tale of science, serendipity, and second chances. Eur. J. Heart Fail. 17, 242\u2013247 (2015).","journal-title":"Eur. J. Heart Fail."},{"key":"52621_CR7","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/s41440-024-01726-3","volume":"47","author":"F Simko","year":"2024","unstructured":"Simko, F. & Baka, T. Pharmacological stimulation of the parasympathetic system \u2013 A promising means of cardioprotection in heart failure. Hypertens Res 47, 2217\u20132220 (2024).","journal-title":"Hypertens Res"},{"key":"52621_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4149\/gpb_2012_015","volume":"31","author":"Z Nichtova","year":"2012","unstructured":"Nichtova, Z., Novotova, M., Kralova, E. & Stankovicova, T. Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol. Gen. Physiol. Biophys. 31, 141\u2013151 (2012).","journal-title":"Gen. Physiol. Biophys."},{"key":"52621_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10741-007-9007-4","volume":"12","author":"OE Osadchii","year":"2007","unstructured":"Osadchii, O. E. Cardiac hypertrophy induced by sustained \u03b2-adrenoreceptor activation: Pathophysiological aspects. Heart Fail. Rev. 12, 66\u201386 (2007).","journal-title":"Heart Fail. Rev."},{"key":"52621_CR10","doi-asserted-by":"publisher","first-page":"H2410","DOI":"10.1152\/ajpheart.2001.281.6.H2410","volume":"281","author":"FHH Leenen","year":"2001","unstructured":"Leenen, F. H. H., White, R. & Yuan, B. Isoproterenol-induced cardiac hypertrophy: Role of circulatory versus cardiac renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol. 281, H2410\u2013H2416 (2001).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"52621_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/01.HYP.19.6.708","volume":"19","author":"M Nagano","year":"1992","unstructured":"Nagano, M. et al. Role of cardiac Angiotensin II in Isoproterenol-induced left ventricular hypertrophy. Hypertension 19, 708\u2013712 (1992).","journal-title":"Hypertension"},{"key":"52621_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/CS20120519","volume":"125","author":"\u00c1PS Souza","year":"2013","unstructured":"Souza, \u00c1. P. S. et al. Angiotensin II type 1 receptor blockade restores Angiotensin-(1\u20137)-induced coronary vasodilation in hypertrophic rat hearts. Clin. Sci. 125, 449\u2013459 (2013).","journal-title":"Clin. Sci."},{"key":"52621_CR13","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/biomedicines10081844","volume":"10","author":"F Simko","year":"2022","unstructured":"Simko, F. et al. Sacubitril\/valsartan and Ivabradine attenuate left ventricular remodelling and dysfunction in spontaneously hypertensive rats: Different interactions with the renin\u2013angiotensin\u2013aldosterone system. Biomedicines 10, 1844 (2022).","journal-title":"Biomedicines"},{"key":"52621_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116391","volume":"173","author":"F Simko","year":"2024","unstructured":"Simko, F. et al. Effect of Sacubitril\/valsartan on the hypertensive heart in continuous light-induced and Lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system. Biomed. Pharmacother. 173, 116391 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"52621_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/biomedicines12040733","volume":"12","author":"P Stanko","year":"2024","unstructured":"Stanko, P. et al. Sacubitril\/valsartan alleviates cardiac remodeling and dysfunction in L-NAME-induced hypertension and hypertensive heart disease. Biomedicines 12, 733 (2024).","journal-title":"Biomedicines"},{"key":"52621_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.696472","volume":"12","author":"M Wu","year":"2021","unstructured":"Wu, M., Guo, Y., Wu, Y., Xu, K. & Lin, L. Protective effects of Sacubitril\/valsartan on cardiac fibrosis and function in rats with experimental myocardial infarction involves inhibition of collagen synthesis by myocardial fibroblasts through downregulating TGF-\u03b21\/Smads pathway. Front. Pharmacol. 12, 696472 (2021).","journal-title":"Front. Pharmacol."},{"key":"52621_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95988-3","volume":"11","author":"X Li","year":"2021","unstructured":"Li, X., Braza, J., Mende, U., Choudhary, G. & Zhang, P. Cardioprotective effects of early intervention with Sacubitril\/valsartan on pressure overloaded rat hearts. Sci Rep 11, 16542 (2021).","journal-title":"Sci Rep"},{"key":"52621_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jacbts.2020.07.006","volume":"5","author":"D Croteau","year":"2020","unstructured":"Croteau, D. et al. Differential effects of sacubitril\/valsartan on diastolic function in mice with obesity-related metabolic heart disease. JACC Basic. Transl Sci. 5, 916\u2013927 (2020).","journal-title":"JACC Basic. Transl Sci."},{"key":"52621_CR19","doi-asserted-by":"crossref","unstructured":"Liu, J. & Rigel, D. F. Echocardiographic examination in rats and mice In (ed. DiPetrillo, K.) (2009).","DOI":"10.1007\/978-1-60761-247-6_8"},{"key":"52621_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00408642","volume":"163\/164","author":"V Pelouch","year":"1996","unstructured":"Pelouch, V. et al. Cardiac phosphocreatine deficiency induced by GPA during postnatal development in rat. Mol. Cell. Biochem. 163\/164, 67\u201376 (1996).","journal-title":"Mol. Cell. Biochem."},{"key":"52621_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0009-9120(96)00003-6","volume":"29","author":"G Kesava Reddy","year":"1996","unstructured":"Kesava Reddy, G. & Enwemeka, C. S. A simplified method for the analysis of hydroxyproline in biological tissues. Clin. Biochem. 29, 225\u2013229 (1996).","journal-title":"Clin. Biochem."},{"key":"52621_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","volume":"69","author":"R Basu","year":"2017","unstructured":"Basu, R. et al. Roles of angiotensin peptides and recombinant human ACE2 in heart failure. J. Am. Coll. Cardiol. 69, 805\u2013819 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"52621_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1373\/clinchem.2017.278705","volume":"64","author":"N Pavo","year":"2018","unstructured":"Pavo, N. et al. Low- and high-renin heart failure phenotypes with clinical implications. Clin. Chem. 64, 597\u2013608 (2018).","journal-title":"Clin. Chem."},{"key":"52621_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","volume":"76","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin II ratio in patients with primary aldosteronism. Hypertension 76, 488\u2013496 (2020).","journal-title":"Hypertension"},{"key":"52621_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1161\/HYPERTENSIONAHA.119.13772","volume":"75","author":"J Burrello","year":"2020","unstructured":"Burrello, J. et al. Renin-angiotensin-aldosterone system triple-A analysis for the screening of primary aldosteronism. Hypertension 75, 163\u2013172 (2020).","journal-title":"Hypertension"},{"key":"52621_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116534","volume":"174","author":"L Flori","year":"2024","unstructured":"Flori, L. et al. The isoproterenol-induced myocardial fibrosis: A biochemical and histological investigation. Biomed. Pharmacother. 174, 116534 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"52621_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jpi.12154","volume":"57","author":"F Simko","year":"2014","unstructured":"Simko, F. et al. Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. J. Pineal Res. 57, 177\u2013184 (2014).","journal-title":"J. Pineal Res."},{"key":"52621_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/fcp.12620","volume":"35","author":"F Simko","year":"2021","unstructured":"Simko, F. et al. Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury. Fundam. Clin. Pharmacol. 35, 744\u2013748 (2021).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"52621_CR29","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3390\/ijms19103017","volume":"19","author":"F Simko","year":"2018","unstructured":"Simko, F. et al. Effect of ivabradine on a hypertensive heart and the renin-angiotensin-aldosterone system in L-NAME-induced hypertension. IJMS 19, 3017 (2018).","journal-title":"IJMS"},{"key":"52621_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/00001573-200007000-00010","volume":"15","author":"KT Weber","year":"2000","unstructured":"Weber, K. T. Fibrosis and hypertensive heart disease. Curr. Opin. Cardiol. 15, 264\u2013272 (2000).","journal-title":"Curr. Opin. Cardiol."},{"key":"52621_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-4684-0940-6_4","volume-title":"Control of Renin Secretion","author":"IA Reid","year":"1972","unstructured":"Reid, I. A., Schrier, R. W. & Earley, L. E. Effect of beta-adrenergic stimulation on renin release. In Control of Renin Secretion Vol. 17 (ed. Assaykeen, T. A.) 49\u201364 (Springer US, 1972)."},{"key":"52621_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0008-6363(97)00212-5","volume":"37","author":"D Grimm","year":"1998","unstructured":"Grimm, D. Development of heart failure following isoproterenol administration in the rat: Role of the renin\u2013angiotensin system. Cardiovasc. Res. 37, 91\u2013100 (1998).","journal-title":"Cardiovasc. Res."},{"key":"52621_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00005344-200208000-00010","volume":"40","author":"MP Ocaranza","year":"2002","unstructured":"Ocaranza, M. P. et al. Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis. J. Cardiovasc. Pharmacol. 40, 246\u2013254 (2002).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"52621_CR34","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/cvr\/28.12.1835","volume":"28","author":"T Omura","year":"1994","unstructured":"Omura, T., Kim, S., Takeuchi, K., Iwao, H. & Takeda, T. Transforming growth factor PI and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: Effects of inhibition of the renin-angiotensin system. Cardiovasc. Res. 28, 1835\u20131842 (1994).","journal-title":"Cardiovasc. Res."},{"key":"52621_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep18582","volume":"5","author":"Q Liu","year":"2015","unstructured":"Liu, Q. et al. Renal denervation findings on cardiac and renal fibrosis in rats with isoproterenol induced cardiomyopathy. Sci. Rep. 5, 18582 (2015).","journal-title":"Sci. Rep."},{"key":"52621_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","volume":"69","author":"T-D Wang","year":"2017","unstructured":"Wang, T.-D. et al. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension 69, 32\u201341 (2017).","journal-title":"Hypertension"},{"key":"52621_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/phrs.2001.0865","volume":"44","author":"M Gallego","year":"2001","unstructured":"Gallego, M. et al. Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. Pharmacol. Res. 44, 311\u2013315 (2001).","journal-title":"Pharmacol. Res."},{"key":"52621_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yjmcc.2019.01.013","volume":"128","author":"TA Meyers","year":"2019","unstructured":"Meyers, T. A. et al. Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts. J. Mol. Cell. Cardiol. 128, 51\u201361 (2019).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"52621_CR39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.yjmcc.2007.01.012","volume":"42","author":"GX Zhang","year":"2007","unstructured":"Zhang, G. X. et al. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J. Mol. Cell. Cardiol. or. J. Mol. Cell. Cardiol. 42, 804\u2013811 (2007).","journal-title":"J. Mol. Cell. Cardiol. or. J. Mol. Cell. Cardiol."},{"key":"52621_CR40","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1124\/jpet.103.063388","volume":"309","author":"R Bos","year":"2004","unstructured":"Bos, R., Mougenot, N., M\u00e9diani, O., Vanhoutte, P. M. & Lechat, P. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. J. Pharmacol. Exp. Ther. 309, 1160\u20131166 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"52621_CR41","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/01.HYP.0000164567.62172.c5","volume":"45","author":"DGA Veliotes","year":"2005","unstructured":"Veliotes, D. G. A. et al. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by \u03b2-adrenoreceptor activation. Hypertension 45, 914\u2013920 (2005).","journal-title":"Hypertension"},{"key":"52621_CR42","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1248\/bpb.b17-00291","volume":"40","author":"Y Hori","year":"2017","unstructured":"Hori, Y. et al. The aldosterone receptor antagonist eplerenone inhibits isoproterenol-induced collagen-I and 11\u03b2-HSD1 expression in rat cardiac fibroblasts and the left ventricle. Biol. Pharm. Bull. 40, 1716\u20131723 (2017).","journal-title":"Biol. Pharm. Bull."},{"key":"52621_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1113\/expphysiol.2011.063230","volume":"97","author":"B Mart\u00edn-Fern\u00e1ndez","year":"2012","unstructured":"Mart\u00edn-Fern\u00e1ndez, B. et al. Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: Involvement of serum\u2010 and glucocorticoid\u2010regulated kinase type 1. Exp. Physiol. 97, 710\u2013718 (2012).","journal-title":"Exp. Physiol."},{"key":"52621_CR44","doi-asserted-by":"publisher","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","volume":"316","author":"RAS Santos","year":"2019","unstructured":"Santos, R. A. S. et al. The renin-angiotensin system: Going beyond the classical paradigms. Am. J. Physiol. Heart Circ. Physiol. 316, H958\u2013H970 (2019).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"52621_CR45","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1042\/CS20200922","volume":"134","author":"UM Steckelings","year":"2020","unstructured":"Steckelings, U. M. & Sumners, C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin Sci (Lond) 134, 2987\u20133006 (2020).","journal-title":"Clin Sci (Lond)"},{"key":"52621_CR46","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.3390\/ijms22063217","volume":"22","author":"F Simko","year":"2021","unstructured":"Simko, F., Hrenak, J., Adamcova, M. & Paulis, L. Renin\u2013angiotensin\u2013aldosterone system: Friend or foe\u2014the matter of balance. Insight on history, therapeutic implications and COVID-19 interactions. Int. J. Mol. Sci. 22, 3217 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"52621_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.842512","volume":"13","author":"F Simko","year":"2022","unstructured":"Simko, F. & Baka, T. Commentary: Effect of angiotensin-converting-enzyme inhibitor and angiotensin II receptor antagonist treatment on ACE2 expression and SARS-CoV-2 replication in primary airway epithelial cells. Front. Pharmacol. 13, 842512 (2022).","journal-title":"Front. Pharmacol."},{"key":"52621_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1152\/physiolgenomics.00227.2003","volume":"17","author":"RAS Santos","year":"2004","unstructured":"Santos, R. A. S. et al. Expression of an angiotensin-(1\u20137)-producing fusion protein produces cardioprotective effects in rats. Physiol. Genomics 17, 292\u2013299 (2004).","journal-title":"Physiol. Genomics"},{"key":"52621_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1753944709353426","volume":"4","author":"AJ Ferreira","year":"2010","unstructured":"Ferreira, A. J. et al. Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1\u20137)-producing fusion protein in the heart. Ther. Adv. Cardiovasc. Dis. 4, 83\u201396 (2010).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"52621_CR50","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.lfs.2007.07.022","volume":"81","author":"AJ Ferreira","year":"2007","unstructured":"Ferreira, A. J. et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1\u20137) analogue AVE 0991. Life Sci. 81, 916\u2013923 (2007).","journal-title":"Life Sci."},{"key":"52621_CR51","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","volume":"57","author":"FD Marques","year":"2011","unstructured":"Marques, F. D. et al. An oral formulation of angiotensin-(1\u20137) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 57, 477\u2013483 (2011).","journal-title":"Hypertension"},{"key":"52621_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045564","volume":"7","author":"M Flores-Mu\u00f1oz","year":"2012","unstructured":"Flores-Mu\u00f1oz, M., Godinho, B. M. D. C., Almalik, A. & Nicklin, S. A. Adenoviral delivery of angiotensin-(1\u20137) or angiotensin-(1\u20139) inhibits cardiomyocyte hypertrophy via the Mas or angiotensin type 2 receptor. PLoS One 7, e45564 (2012).","journal-title":"PLoS One"},{"key":"52621_CR53","doi-asserted-by":"publisher","first-page":"H1057","DOI":"10.1152\/ajpheart.00433.2013","volume":"305","author":"AM Lima","year":"2013","unstructured":"Lima, A. M. et al. Activation of angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis attenuates the cardiac reactivity to acute emotional stress. Am. J. Physiol. Heart Circ. Physiol. 305, H1057\u2013H1067 (2013).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"52621_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-014-0433-0","volume":"16","author":"GM Etelvino","year":"2014","unstructured":"Etelvino, G. M., Peluso, A. A. B. & Santos, R. A. S. New components of the Renin-Angiotensin System: Alamandine and the Mas-related G protein-coupled receptor D. Curr. Hypertens. Rep. 16, 433 (2014).","journal-title":"Curr. Hypertens. Rep."},{"key":"52621_CR55","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/ijms17071098","volume":"17","author":"J Hrenak","year":"2016","unstructured":"Hrenak, J., Paulis, L. & Simko, F. Angiotensin A\/alamandine\/MrgD axis: Another clue to understanding cardiovascular pathophysiology. IJMS 17, 1098 (2016).","journal-title":"IJMS"},{"key":"52621_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/01.HYP.0000149105.75125.2a","volume":"45","author":"HM Siragy","year":"2005","unstructured":"Siragy, H. M., Xue, C., Abadir, P. & Carey, R. M. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 45, 133\u2013137 (2005).","journal-title":"Hypertension"},{"key":"52621_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","volume":"125","author":"E Kaschina","year":"2017","unstructured":"Kaschina, E., Namsolleck, P. & Unger, T. AT2 receptors in cardiovascular and renal diseases. Pharmacol. Res. 125, 39\u201347 (2017).","journal-title":"Pharmacol. Res."},{"key":"52621_CR58","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.05.588367","author":"IM Souza-Silva","year":"2024","unstructured":"Souza-Silva, I. M. et al. Angiotensin-(1\u20135) is a potent endogenous angiotensin AT2 -receptor agonist. Preprint at. https:\/\/doi.org\/10.1101\/2024.04.05.588367 (2024).","journal-title":"Preprint at."},{"key":"52621_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.peptides.2016.09.009","volume":"86","author":"L Yu","year":"2016","unstructured":"Yu, L., Yuan, K., Phuong, H. T. A., Park, B. M. & Kim, S. H. Angiotensin-(1\u20135), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor. Peptides 86, 33\u201341 (2016).","journal-title":"Peptides"},{"key":"52621_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2860488","volume":"2021","author":"W Bai","year":"2021","unstructured":"Bai, W. et al. Continuous infusion of angiotensin IV protects against acute myocardial infarction via the inhibition of inflammation and autophagy. Oxid. Med. Cell. Longev. 2021, 2860488 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"52621_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116713","volume":"479","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. Angiotensin IV ameliorates doxorubicin-induced cardiotoxicity by increasing glutathione peroxidase 4 and alleviating ferroptosis. Toxicol. Appl. Pharmacol. 479, 116713 (2023).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"52621_CR62","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.peptides.2011.09.015","volume":"32","author":"H Yang","year":"2011","unstructured":"Yang, H. et al. Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor. Peptides 32, 2108\u20132115 (2011).","journal-title":"Peptides"},{"key":"52621_CR63","doi-asserted-by":"publisher","first-page":"575","DOI":"10.5603\/CJ.a2018.0048","volume":"26","author":"T Miyoshi","year":"2019","unstructured":"Miyoshi, T. et al. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. Cardiol. J. 26, 575\u2013583 (2019).","journal-title":"Cardiol. J."},{"key":"52621_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132203","volume":"409","author":"G Vergaro","year":"2024","unstructured":"Vergaro, G. et al. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction. Int. J. Cardiol. 409, 132203 (2024).","journal-title":"Int. J. Cardiol."},{"key":"52621_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0167-0115(99)00004-X","volume":"80","author":"PJ Mulrow","year":"1999","unstructured":"Mulrow, P. J. Angiotensin II and aldosterone regulation. Regul. Pept. 80, 27\u201332 (1999).","journal-title":"Regul. Pept."},{"key":"52621_CR66","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0196-9781(01)00418-1","volume":"22","author":"P Rebuffat","year":"2001","unstructured":"Rebuffat, P., Malendowicz, L. K., Nussdorfer, G. G. & Mazzocchi, G. Stimulation of endogenous nitric oxide production is involved in the inhibitory effect of adrenomedullin on aldosterone secretion in the rat. Peptides 22, 923\u2013926 (2001).","journal-title":"Peptides"},{"key":"52621_CR67","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s42000-024-00583-6","volume":"23","author":"G Stathori","year":"2024","unstructured":"Stathori, G., Alexakis, D., Chrousos, G. P. & Paltoglou, G. Examining aldosterone plasma concentration alterations post-ACTH stimulation in healthy subjects: A systematic literature review and meta-analysis on ACTH\u2019s role in aldosterone secretion. Hormones 23, 765\u2013775 (2024).","journal-title":"Hormones"},{"key":"52621_CR68","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1210\/en.2010-1070","volume":"152","author":"J Yatabe","year":"2011","unstructured":"Yatabe, J. et al. Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology 152, 1582\u20131588 (2011).","journal-title":"Endocrinology"},{"key":"52621_CR69","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","volume":"8","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt, B. et al. Neprilysin inhibitors in heart failure. JACC. Basic Transl. Sci. 8, 88\u2013105 (2023).","journal-title":"JACC. Basic Transl. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52621-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:03:23Z","timestamp":1783987403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52621"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52621-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21877"}}